CXCL12 and neoplasm: In conclusion, the BM of R patients would benefit by the renewal of the whole microenvironment, due to the efficacy of imatinib mesylate treatment, documented by BMP, BAFF and SDF-1 production, and leading to the development of the observed B cell population producing tumor-reactive IgM.